Bearish flow noted in Crispr Therapeutics with 2,199 puts trading, or 1.1x expected. Most active are Jan-25 40 puts and 1/5 weekly 65 calls, with total volume in those strikes near 2,200 contracts. The Put/Call Ratio is 1.69, while ATM IV is up over 1 point on the day. Earnings are expected on February 20th.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Crispr Therapeutics price target lowered to $100 from $110 at BofA
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics positioned for European approval, says Piper Sandler
- The biopharma stocks to own in 2024, according to Morgan Stanley